Hidden STAT3 Splice Variant Drives Colon Cancer by Bypassing Its Own Brakes
A rogue STAT3 isoform missing a single amino acid evades built-in inflammation controls, fueling colorectal cancer in mice.
Summary
Researchers discovered that a naturally occurring splice variant of STAT3, missing a single amino acid (Ser701), lacks a critical self-regulatory mechanism. Normally, mTORC1 phosphorylates Ser701, which blocks excessive STAT3 activation by limiting access to the key Y705 phosphorylation site. The ΔS701 isoform bypasses this brake, becoming hyperactive during inflammation. This variant is more abundant in human colon cancers. In mouse models, deletion of S701 increased susceptibility to colonic inflammation and tumor development. Importantly, pharmacological inhibition of PP2A — the enzyme that removes the protective phosphate from S701 — reduced colon inflammation in normal mice but not in ΔS701 mice, confirming the mechanism's specificity. These findings reveal how STAT3 isoform diversity shapes cancer risk.
Detailed Summary
STAT3 is one of the most studied proteins in cancer biology, known to drive tumor growth and inflammation when overactivated. Yet the molecular mechanisms that normally keep STAT3 in check — and how cancer cells circumvent them — have remained incompletely understood. This study uncovers a previously overlooked layer of regulation rooted in alternative splicing.
The researchers identified that cryptic splice sites within STAT3 produce two isoforms: one retaining serine at position 701 (wS701) and one lacking it (ΔS701). The ΔS701 isoform was found to be more prevalent in human colon cancer samples, suggesting clinical relevance beyond the mouse model.
Mechanistically, the team showed that mTORC1 phosphorylates S701 under inflammatory conditions, and this phosphorylation physically restricts access of JAK1/2 kinases to the Y705 site — the primary activation switch for STAT3. PP2A reverses this phosphorylation. This dynamic phosphorylation cycle acts as a molecular governor on STAT3 activity. The ΔS701 variant, lacking this residue entirely, cannot be governed this way and remains constitutively hyperactive.
In vivo experiments demonstrated that mice engineered to lack S701 showed heightened colonic inflammation and greater susceptibility to inflammation-associated colorectal tumorigenesis. Pharmacological PP2A inhibition, which would sustain protective p-S701 signaling, reduced colonic inflammation in wild-type mice but had no effect in ΔS701 mice — validating the mechanism's specificity and therapeutic logic.
These findings reframe STAT3 biology by showing that isoform heterogeneity, not just expression level, determines pathological outcomes. The study also positions PP2A inhibition and STAT3 isoform profiling as potential therapeutic and diagnostic strategies. Caveats include reliance on mouse models and the need for human clinical validation.
Key Findings
- A STAT3 splice variant missing Ser701 (ΔS701) is hyperactive and more abundant in human colon cancers.
- mTORC1 phosphorylates S701, blocking JAK1/2 access to Y705 and restraining STAT3 overactivation.
- PP2A removes S701 phosphorylation; its inhibition sustains STAT3 suppression in wild-type but not ΔS701 mice.
- Mice lacking S701 show increased susceptibility to colonic inflammation and colorectal tumorigenesis.
- STAT3 isoform heterogeneity, not just expression level, governs inflammation-to-cancer progression.
Methodology
The study combined biochemical phosphorylation assays, mouse genetic models (S701 deletion knockin), and pharmacological PP2A inhibition experiments. Human colon cancer tissue was analyzed to confirm ΔS701 isoform prevalence. An azoxymethane/DSS mouse model was used to induce colonic inflammation-associated tumorigenesis.
Study Limitations
Findings are primarily from mouse models, and direct causal evidence in human colorectal cancer patients is lacking. The prevalence and functional impact of the ΔS701 isoform across diverse human populations and cancer stages requires further investigation. Long-term safety of PP2A inhibition as a therapeutic strategy has not been assessed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.